Skip to main content
OpenTrials
Completed

NCT Number: NCT03794804

Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate Efficacy of CMS008618 for Common Cold

This study evaluates the impact of ColdZyme® Mouth Spray on quality of life during common cold. Half of the participants will receive ColdZyme® Mouth Spray, half will receive a placebo device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Common Cold Infections Picornaviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinische Forschung Berlin, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women
  • Age 18 to 70 years old
  • Increased risk for common cold (at least 3 self-reported occurences of common cold within the last 12 months prior to V1) but generally in good health
  • Readiness to comply with trial procedures, including in particular:
  • Use of IP as recommended
  • Filling in diary
  • Keeping habitual life-style, including diet and physical activity level
  • No use of products that may influence the study outcome (e.g. immune suppressants/immune stimulants including natural health products, analgesics/anti-rheumatics, anti-phlogistics, anti-tussives/expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray) during the study (except for the defined "rescue" treatment)
  • Women of child-bearing potential:
  • Have to agree to use appropriate contraception methods
  • Negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1

Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature,

Exclusion criteria

  • Known allergy or hypersensitivity to the components of the investigational product
  • History and/or presence of clinically significant condition/ disorder (self-reported), which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:
  • Nasal disorder (e.g. polyposis, relevant septal deviation, ulcer etc.) and/or reconstructive surgery
  • Asthma, chronic obstructive lung disease or any other acute/chronic airways disease/disorder (e.g. chronic cough of any origin)
  • Acute psychiatric disorders
  • Any other acute/chronic serious organ or systemic diseases
  • Influenza vaccination within the last 3 months prior to V1 and during the study
  • Regular use of products that may influence the study outcome (e.g. immune suppressants/immune stimulants including natural health products, analgesics/anti-rheumatics, anti-phlogistics, antitussives/ expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray) within the last 4 weeks prior to V1
  • Pregnancy or nursing
  • History of (in the past 12 months prior to V1) or current abuse of drugs, alcohol or medication
  • Participation in the present study of a person living in the same household as the subject
  • Inability to comply with study requirements according to investigator's judgement
  • Participation in another clinical study in the 30 days prior to V1 and during the study

Treatment and study plan

ColdZyme

Device

ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (<1 %), calcium chloride, trometamol and menthol.

ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.

ColdZyme Placebo

Device

The placebo mouth spray solution has the following composition: ethanol (<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.

Primary outcomes

  1. WURSS-21 QoL sub score

    Time frame: Days 1-8 (day 1 is the first day of symptoms)

    The primary endpoint is the AUC of Wisconsin Upper Respiratory Symptom Survey (WURSS-21) Quality of Life composite subscore during first 8 days of symptoms, to be assessed in comparison between verum and placebo.

Secondary outcomes

  1. 1. Composite daily severity of all symptoms within the Jackson score

    Time frame: Days 1-8 (day 1 is the first day of symptoms)

    The first major secondary endpoint: AUC days 1-8 composite daily severity of all symptoms within the Jackson score (mean of morning and evening) (day 1 is the first day of symptom recording)

  2. 2. Exposure to any concomitant treatment (including natural health products) that may affect common cold symptoms

    Time frame: Days 1-4 (day 1 is the first day of symptoms)

    The second major secondary endpoint: Exposure to any concomitant treatment (including natural health products) that may affect common cold symptoms - immune suppressants/immune stimulants, analgesics/ anti-rheumatics, anti-phlogistics, antitussives/ expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray or any medication/treatment known to affect common cold symptoms - at any dose, expressed as number of days with concomitant treatment during the first 4 days for each subject (based on diary data).

  3. Other secondary endpoints: AUC days 1-8 for each single WURSS-21 QoL subscore item

    Time frame: Days 1-8 (day 1 is the first day of symptoms)

    AUC days 1-8 for each single WURSS-21 QoL subscore item

  4. AUC days 1-8 composite daily severity of all local symptoms within the Jackson score (mean of morning and evening)

    Time frame: Days 1-8 (day 1 is the first day of symptoms)

    AUC days 1-8 composite daily severity of all local symptoms within the Jackson score (mean of morning and evening) item

  5. AUC days 1-8 composite daily severity of each individual symptom of the Jackson score (mean of morning and evening)

    Time frame: Days 1-8 (day 1 is the first day of symptoms)

    AUC days 1-8 composite daily severity of all local symptoms within the Jackson score (mean of morning and evening) item

  6. Frequency of subjects with use of concomitant treatment that may affect common cold symptoms or any medication/treatment known to affect common cold symptoms - at any dose

    Time frame: Days 1-4

    Frequency of subjects with use of concomitant treatment (including natural health products) that may affect common cold symptoms - immune suppressants/immune stimulants, analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray or any medication/treatment known to affect common cold symptoms - at any dose

  7. Assessment of duration of first intense phase

    Time frame: From enrolment through study completion, maximum 16 weeks

    Assessment of duration of first intense phase, expressed as number of days from start of treatment until scoring <5 in total Jackson score

  8. Assessment of symptom intensity

    Time frame: Days 1-4

    Assessment of symptom intensity, expressed as mean total Jackson score days 1-4

  9. Assessment of symptom sore throat per Sore Throat Scale

    Time frame: Days 1-8

    Assessment of symptom sore throat per Sore Throat Scale, expressed as AUC days 1-8

  10. Percentage of subjects with confirmed common cold at Visit 2

    Time frame: 1-3 days after symptom start

    Percentage of subjects with confirmed common cold at Visit 2 (from all subjects with V2), which should take place within 1-3 days after symptom start

  11. Global evaluation of efficacy by subjects and investigators at study end

    Time frame: From enrolment through study completion, maximum 16 weeks

    Global evaluation of efficacy by subjects and investigators at study end, 4-point categorical scale: "very good", "good", "moderate" and "poor"

Other outcomes

  1. Safety endpoint: Physical examination

    Time frame: From enrolment through study completion, maximum 16 weeks

    Physical examination: standard clinical examination of the gastrointestinal tract, cardiovascular system, eyes, respiratory tract, lymph nodes, musculoskeletal system, neurological functions, urogenital tract, thyroid gland and skin.

  2. Safety endpoint: Vital signs

    Time frame: From enrolment through study completion, maximum 16 weeks

    Vital signs: blood pressure (mmHg)

  3. Safety endpoint: Vital signs

    Time frame: From enrolment through study completion, maximum 16 weeks

    Vital signs: pulse rate (bpm)

  4. Safety endpoint: Global evaluation of tolerability by subjects and investigators

    Time frame: From enrolment through study completion, maximum 16 weeks

    Global evaluation of tolerability by subjects and investigators at study end, 4-point categorical scale: "very good", "good", "moderate" and "poor"

  5. Safety endpoint: Assessment of adverse events

    Time frame: From enrolment through study completion, maximum 16 weeks

    Assessment of adverse events throughout the study

  6. Safety endpoint: Assessment of device deficiencies

    Time frame: From enrolment through study completion, maximum 16 weeks

    Assessment of device deficiencies at V2 and V3

Sponsors and collaborators

Lead sponsor

Enzymatica AB

Industry

Collaborators

  • Analyze & Realize

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jan 7, 2019
Registry last updated
Aug 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.